Diagnostic performance of a SARS-CoV-2 IgG/IgM lateral flow immunochromatography assay in symptomatic patients presenting to the emergency department
Detection Principle
ImmunoAssay-Antibody
Target
IgG and IgM
Testing Method Category
LFIA
Testing Method
Maccura LFIA (SARS-CoV-2 IgM/IgG, Maccura Biotechnology, Chengdu, China)
Testing Method - Additional Info
LFIA compared to SARS-CoV-2 RT-PCR (Seegene Inc., Seoul, Republic of Korea)
Reported Performance
PPV: 81% IgM and/or IgG), 100% (double positive IgM and IgG)
Sample Size
315 samples
Peer-reviewed
yes
The database contains available information from scientific literature that is being updated periodically. Please note that the provided information (as retrieved from analysed papers) is provided only for devices commercially available with CE-IVD mark. Acknowledgements